Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS -- Ignore unavailable to you. Want to Upgrade?

To: H. Bradley Toland, Jr. who wrote (344)	8/17/1998 5:57:00 PM
From: Caveat Emptor	Read Replies (1) \| Respond to of 410

How do you define "impact" Brad..... According to the Herald artical, the stock price dove $1 1/16 the day before the announcement to $29.00. The way I read it, and I may be wrong, but a test kit can be sold. Selling this kit increases earnings (short and long) into the corporation, otherwise, why go through the FDA process, and the trouble of making the kit. With the delay of this approval because of the company's internal breakdown, this potential income is now wiped out (at least till they resubmit). Loss of income disturbs me, especially if it is caused by events which could have been prevented by proper management and supervision. The spin is weak. I disagree with "no impact whatsoever to earnings". How can that argument be supported? Sales of test kits = earnings! We seem to need all the earnings we can get at the moment. CAVEAT EMPTOR